Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,793 total articles
AbbVie delivered a convincing Q1 with $15 billion revenue and accelerating Skyrizi and Rinvoq growth. The company generates roughly $17.8 billion in free cash flow and yields 3.3%, yet the stock trades at lofty multiples that still underprice durable growth. We present a long trade to capture a re-rating as clinical catalysts, label expansions, and…
Tennessee Valley Authority 1999 Series A bonds (TVE) trade at $23.70, yield a modest quarterly distribution and sit below recent moving averages. Fundamentals are mixed - government-backed power operations with thin liquidity and negative free cash flow - but the combination of an imminent distribution, a discounted price to recent highs, and an RS…
Erasca (ERAS) sits squarely between high upside from ERAS-0015 clinical progress and material headline risk from a patent infringement claim and a securities investigation. We recommend Hold: existing holders should keep positions sized but use a hard stop; new entrants should wait for clearer data or a resolution of the legal noise. Trade plan pro…
Ares Capital (ARCC) offers a rare 10%+ yield, but underlying earnings, interest-rate sensitivity and rising short interest suggest the stock is likely to remain rangebound or slip lower over the next several weeks. This trade proposes a tactical short for the mid term (45 trading days) with tight risk controls.
AvePoint has pulled back toward the recent low after a volatile month, but fundamentals and product-led catalysts suggest a recovery path. At roughly $2.2B market cap and positive free cash flow, the stock can re-rate if execution on product expansion and SGX listing drive revenue and margin visibility. This trade lays out an entry at $10.50, a tig…
CoinShares, a leading European digital-asset manager, offers an asymmetric risk-reward for traders willing to own the name through a recovering crypto cycle. This trade targets a near-term re-acceleration in product inflows and a re-rating if Bitcoin-related ETFs keep attracting assets. Entry, stop and target laid out with clear horizons and risk c…
Alphabet is the highest-conviction pick among mega-cap tech names right now. Strong AI positioning, healthy free cash flow ($64.4B), and a pristine balance sheet offset a premium multiple (PE ~30). This trade targets a disciplined long-term entry at $390.00 with a $425.00 target and a $365.00 stop, delivering a favorable risk/reward while respectin…
DMLP’s headline distribution weakness has rattled the stock, but underlying cash generation and a conservative balance sheet justify a tactical long. The partnership trades below its short-term moving averages with an attractive forward yield and reasonable valuation metrics (EV/EBITDA ~7.9). For traders willing to accept mid-term volatility, a buy…
FANUC remains the most visible vendor in factory robotics and CNC systems. Technical momentum and favorable market dynamics support a tactical long over the next 45 trading days, while valuation is rich and execution risks remain. Trade plan provided with clear entry, stop, and target.
Vistra (VST) owns dispatchable capacity, long-term customer deals and nuclear-linked supply that position it as a direct beneficiary of rising AI/data-center electricity demand. The stock has pulled back from its 52-week high and shows technical weakness, but fundamentals - enterprise value of ~$69.3B, free cash flow of $1.318B and a $50.6B market …
Palantir's recent earnings and signs of accelerating commercial adoption put it squarely in the path of two structural tails - industrial reshoring and rising defense spending. The business shows healthy profitability and strong free cash flow, but the stock trades at premium multiples. This trade idea lays out an actionable long with explicit entr…
monday.com (MNDY) has been re-priced hard since its 2025-2026 guidance reversal, but recent technical strength, crowded short positioning, and still-elevated investor expectations around AI monetization create a tactical long opportunity. This trade idea outlines an entry at $76.20, a stop at $66.00 and a target at $110.00 for a mid-term (45 tradin…
Super Micro (SMCI) has historically been a leveraged play on hyperscaler and enterprise AI spending. With AI infrastructure budgets accelerating across the supply chain, the stock looks set for a bounce. This trade idea lays out an actionable entry, target, and stop with a mid-term horizon while flagging the company-specific and macro risks that ma…
Mativ has moved from cyclical weakness toward positive free cash flow and an attractive valuation. At a market cap around $503M and P/E under 7, the upside to $12.50 looks reachable if margins stabilize and the company sustains cash conversion. This is a speculative, risk-managed trade for investors willing to accept execution and leverage risk.
Brookfield Asset Management (BAM) is trading near $49 with a rich yield and improving earnings quality. Growing fee-related earnings (FRE) and distributable earnings (DE), plus recent industrial acquisitions and strong governance, support a long trade over the next 180 trading days. Valuation looks expensive on headline P/E, but the combination of …
Microsoft remains a core play on enterprise AI and cloud adoption. Fundamentals - a $3.05T market cap, 18% trailing revenue growth narrative, strong cash flow and 30% ROE - back continued upside. Technicals are mixed, so treat this as a structured swing trade: entry near $411, stop at $395, target $470 over the next 45 trading days.
Kratos has been sharply repriced since its 52-week high but remains a growing supplier to U.S. national security programs in unmanned systems, hypersonics test infrastructure, and mission-critical RF/space electronics. The balance sheet is clean, valuation is rich versus earnings but reasonable relative to growth optionality; this trade idea buys t…
Abbott ($83.55) is trading near multi-year lows while sitting on three structural growth drivers - continuous glucose monitoring (CGM), diagnostics expansion, and a nutrition recovery. Fundamentals show solid cash generation, a reasonable 23x P/E and a 2.9% yield. Technicals are deeply oversold. This trade idea lays out an actionable entry at $83.5…
Micron has been the poster child of the 2026 memory rally, but beneath the parabolic move the company still posts strong cash generation, clean leverage and profitable returns that argue for a disciplined long. This trade idea buys a pullback for exposure to secular AI capex while keeping a tight stop to protect against memory-cycle reversals.
Shinhan Financial (SHG) trades at a sub-1x PB and single-digit PE with a 2.0% yield and a management bias toward improving distributions. We recommend a tactical long position to capture upside from valuation re-rating and potential higher dividend/extra cash returns over the next 3-6 months, while protecting capital with a disciplined stop.
Sentiment that Greggs has hit its ceiling is premature. A recent trip to London and conversations with managers, franchisees and store teams show demand still rising, new product tails gaining traction, and store economics improving. This trade idea outlines a long entry, layered targets across horizons, and the risks that could derail the thesis.
Palantir (PLTR) has re-priced lower after a stretch of execution skepticism. The shares now offer a high-conviction, defined-risk swing trade: buy into improving AI monetization and persistent government contracts with clear stops and two-tier targets. This plan balances upside from product-led revenue expansion against execution and concentration …
Micron has gone from the low $90s to roughly $780 in a year. Fundamentals - strong free cash flow, healthy margins and low leverage - plus AI-driven memory demand are keeping the stock bid. This is a momentum trade: enter on strength with a clear stop and a ~20% upside target over the next 45 trading days while respecting high overbought signals an…
L3Harris has the cash flow, backlog exposure and recent capacity investments to absorb short-term pressure and deliver medium-to-long-term upside. With free cash flow of $2.59B, an EV of roughly $66.6B and a dividend yield near 1.6%, the shares look buyable around current levels given an improving defense demand backdrop and concrete manufacturing …
Herbalife (HLF) is trading at a deep discount to both earnings and cash flow, with free cash flow of $373.9M against a market cap near $1.45B. Technicals show oversold momentum while short interest and heavy short-volume suggest a path for a squeeze. We lay out an actionable mid-term trade with entry, stop, and target based on fundamentals and the …
